Compare · ABT vs MNKD
ABT vs MNKD
Side-by-side comparison of Abbott Laboratories (ABT) and MannKind Corporation (MNKD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and MNKD operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $175.37B, about 140.8x MNKD ($1.25B).
- Over the past year, ABT is down 18.6% and MNKD is up 7.3% - MNKD leads by 25.9 points.
- ABT has been more active in the news (12 items in the past 4 weeks vs 8 for MNKD).
- ABT has more recent analyst coverage (25 ratings vs 14 for MNKD).
- Company
- Abbott Laboratories
- MannKind Corporation
- Price
- $100.68+1.91%
- $4.03-0.49%
- Market cap
- $175.37B
- $1.25B
- 1M return
- +11.09%
- +4.01%
- 1Y return
- -18.60%
- +7.33%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2004
- News (4w)
- 12
- 8
- Recent ratings
- 25
- 14
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension; and Thirona Bio to evaluate the therapeutic potential of TGF-Ã inhibitor for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
Latest MNKD
- Chief Financial Officer Prentiss Christopher B covered exercise/tax liability with 22,247 shares, decreasing direct ownership by 7% to 318,668 units (SEC Form 4)
- Pres, Endocrine Business Unit Marasco Dominic covered exercise/tax liability with 3,623 shares, decreasing direct ownership by 1% to 343,398 units (SEC Form 4)
- Chief People & Workpl Officer Tross Stuart A converted options into 93,790 shares and covered exercise/tax liability with 65,808 shares, increasing direct ownership by 3% to 1,058,142 units (SEC Form 4)
- Chief Executive Officer Castagna Michael converted options into 350,260 shares and covered exercise/tax liability with 363,200 shares, decreasing direct ownership by 0.53% to 2,433,779 units (SEC Form 4)
- EVP Technical Operations Singh Sanjay R converted options into 70,550 shares and covered exercise/tax liability with 46,795 shares, increasing direct ownership by 5% to 478,966 units (SEC Form 4)
- EVP Genl Counsel & Secretary Thomson David covered exercise/tax liability with 98,426 shares, sold $97,641 worth of shares (24,109 units at $4.05) and converted options into 93,790 shares, decreasing direct ownership by 3% to 797,554 units (SEC Form 4)
- Director Binder Steven B. sold $213,089 worth of shares (52,485 units at $4.06), converted options into 93,790 shares and covered exercise/tax liability with 24,395 shares, increasing direct ownership by 2% to 824,918 units (SEC Form 4)
- MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
- Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
- MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF